Meghan Moore Burk

Meghan Moore Burk

Auto-generated profile, based on publicly available information

Meghan Moore Burk

Children's Hospital Colorado

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2021 in Neurorehabilitation and Neural Repair
Verified
Journal Article
Closed access
PDF file
JKJohn W. Krakauer
John W. Krakauer
TKTomoko Kitago
Tomoko Kitago
JGJeff Goldsmith
Jeff Goldsmith
OAOmar Ahmad
Omar Ahmad
PRPromit Roy
Promit Roy
ALAndreas R. Luft
Andreas R. Luft
Evidence from animal studies suggests that greater reductions in poststroke motor impairment can be attained with significantly higher doses and intensities of therapy focused on movement quality. These studies also indicate a dose-timing interaction, with more pronounced effects if high-intensity therapy is delivered in the acute/subacute, rather than chronic, poststroke period. To compare 2 approaches of delivering high-intensity, high-dose upper-limb therapy in patients with subacute stroke: a novel exploratory neuroanimation therapy (NAT) and modified conventional occupational therapy (COT). A total of 24 patients were randomized to NAT or COT and underwent 30 sessions of 60 minutes time-on-task in addition to standard care. The primary outcome was the Fugl-Meyer Upper Extremity motor score (FM-UE). Secondary outcomes included Action Research Arm Test (ARAT), grip strength, Stroke Impact Scale hand domain, and upper-limb kinematics. Outcomes were assessed at baseline, and days 3, 90, and 180 posttraining. Both groups were compared to a matched historical cohort (HC), which received only 30 minutes of upper-limb therapy per day. There were no significant between-group differences in FM-UE change or any of the secondary outcomes at any timepoint. Both high-dose groups showed greater recovery on the ARAT (7.3 ± 2.9 points; P = .011) but not the FM-UE (1.4 ± 2.6 points; P = .564) when compared with the HC. Neuroanimation may offer a new, enjoyable, efficient, and scalable way to deliver high-dose and intensive upper-limb therapy.

30 December 2025 in Journal of Neuromuscular Diseases
Verified
Journal Article
Open access
MBMeghan Moore Burk
Meghan Moore Burk
TCThomas O Crawford
Thomas O Crawford
KJKristen Johnson
Kristen Johnson
SASusan Apkon
Susan Apkon
LBLaurey Brown
Laurey Brown
KKKristin J. Krosschell
Kristin J. Krosschell
Background: The clinical course of Spinal Muscular Atrophy (SMA) has been transformed by new disease-modifying therapies (DMT). Before DMT, the clinical course of SMA was marked by an inflection point between developmental improvement and degenerative functional losses. The well-established SMA classification by “type” was based upon the age and functional level at which this inflection point manifested. Following DMT, the natural history of SMA has evolved. The evolution of the SMA clinical course following DMT thus necessitates an updated means to characterize individuals with SMA. Objective: To address both clinical and research needs, an updated assessment should target meaningful function; apply broadly across the range of SMA; maximize the granularity of functional tiers with minimal compromise of reliability; require minimal or no specific training; and be validated with measurable consistency between both naïve and experienced clinicians, and between these clinicians and members of the SMA community. Methods/Design: Development of the Functional Ability Scale for Evolving SMA (EVOLVE-SMA) proceeded as an iterative scale creation and refinement process using retrospective cohorts (for design, reliability, and validity) followed by prospective assessments of real-world feasibility and reliability. Results: Excellent interrater reliability (ICC >0.9, p < 0.001) was established between expert and novice clinicians (physician and physical therapist) and clinicians versus SMA community members. Conclusions: EVOLVE-SMA is a tiered evaluation of function applicable to the new DMT-treated era of SMA. It is a simple, granular, and reliable means to assess meaningful functions that will have value to research, resource allocation, and individual clinical care.

28 August 2026 in Muscle & Nerve
Verified
Journal Article
Closed access
MBMeghan Moore Burk
Meghan Moore Burk
CKCarolyn Kelley
Carolyn Kelley
STSara Thinger
Sara Thinger
HFHattie Foster
Hattie Foster
KJKelli Johnson
Kelli Johnson
MYMichele L. Yang
Michele L. Yang

7 April 2026 in Journal of Neuromuscular Diseases
Verified
Journal Article
Open access
KKKristin J. Krosschell
Kristin J. Krosschell
SYSally Dunaway Young
Sally Dunaway Young
EMElizabeth Maczek
Elizabeth Maczek
LBLaurey Brown
Laurey Brown
KHKatie Hoffman
Katie Hoffman
ZZZarazuela Zolkipli-Cunningham
Zarazuela Zolkipli-Cunningham
Background: Approved disease modifying treatments (DMTs) and the implementation of newborn screening for spinal muscular atrophy (SMA) have allowed individuals treated early to gain new motor abilities and achieve more typical motor milestones. In this changing landscape, current motor function outcome measures (MF-OMs) used in SMA clinical practice may no longer be sufficiently sensitive enough to optimally quantify new disease trajectories and evolving functional progression. Objective: To develop a consensus-derived recommendation for MF-OMs to be used in assessing infants and children living with SMA who were treated with DMTs very early in life. Methods: A modified Delphi methodology which included three web-based surveys and virtual conferences was conducted with an international group of multidisciplinary experts treating infants and children living with SMA who were treated early. Community input was also collected via semi-structured interviews. Results: A consensus-derived recommendation for MF-OMs to be routinely administered in early treated infants and children living with SMA was developed. Consensus recommendations included both SMA-specific and non SMA-specific MF-OMs for five age periods. MF-OMs were inclusive of Clinician-Reported, Caregiver/Patient-Reported, and Performance/Functional Outcome Measures. Recommendations on optimal assessment frequency varied across age periods from quarterly to bi-annually. Conclusions: Clinicians with expertise in SMA achieved consensus on establishing relevant MF-OMs to implement from infancy through childhood to track motor progress in early treated infants. Routine data collection using recommended MF-OMs will facilitate cohort comparison for research collaborations to better understand new disease trajectories and motor progression of this population.